Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

New artificial intelligence model detects tissue damage in the heart

Researchers from the COR group at the Institute of Information and Communications Technologies (ITACA) of the Universitat Politècnica de València (UPV) have developed an artificial intelligence model capable of localizing and quantifying tissue abnormalities associated with atrial cardiomyopathy using electrical recordings from the body's surface.

28 Sep 2026

New framework maps the complex link between psychological status and cardiovascular health

CVD remains the leading cause of death worldwide, while the global burden of mental disorders continues to rise.

28 Sep 2026

In vivo CAR-T therapy transforms customized treatments into universal medicines

A collaborative team led by Professor Huji Xu from Naval Medical University, China, together with Professors Xuanming Yang and Yujia Cai at Shanghai Jiao Tong University, China, published a comprehensive review in Volume 2, article number 33 of the journal Immunity & Inflammation on August 31, 2026.

25 Sep 2026

Study identifies shared pathway driving cardiac fibrosis

Three adenosine receptor subtypes that normally send different signals were found to converge on a common pathway that activates cardiac fibroblasts, the scar-forming cells in the heart.

24 Sep 2026

Mount Sinai researchers discover how Alzheimer's gene damages blood vessels

Mount Sinai researchers have identified how APOE4, the strongest genetic risk factor for Alzheimer's disease, damages the brain's blood vessels and promotes the buildup of abnormal proteins linked to neurodegenerative disease.

24 Sep 2026

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

A brief report reviews emerging GLP-1 receptor co-agonists that also target GIPR, GCGR, and other receptors, examining their metabolic benefits alongside known and predicted cardiac effects. The authors highlight substantial species differences, warning that mouse heart studies may fail to predict responses in human cardiac tissue and that many proposed cardiac effects still require direct testing.

24 Sep 2026

Baseline liver fibrosis severity predicts treatment response in patients with HBeAg-positive CHB

The impact of baseline liver fibrosis severity on the effectiveness of pegylated interferon (Peg-IFN) combined with nucleos(t)ide analogs (NAs) in the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) has not been fully clarified.

23 Sep 2026

Marine carbohydrates offer valuable new resources for drug development

The ocean contains diverse carbohydrates that could serve as valuable resources for drug development. Algae, marine animals and microorganisms produce polysaccharides and related molecules with structures that are uncommon on land, including distinctive sulfate patterns, sugar linkages and branched architectures.

22 Sep 2026

Siemens Healthineers and Novo join forces to advance care for people living with MASLD and MASH

Siemens Healthineers and Novo have announced a collaboration focused on advancing care for people living with metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH).

From Siemens Healthineers 22 Sep 2026

Celastrol reduces cholestatic liver injury by inhibiting specific protein

Cholestasis occurs when bile formation, secretion, or flow is impaired, causing toxic bile acids to accumulate and trigger inflammation and liver-cell damage.

17 Sep 2026

Study identifies bile acid that helps reduce excess fat accumulation in the liver

Non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common condition that causes excess fat to build up in the liver, affecting about one-quarter of adults worldwide.

17 Sep 2026

Study defines early-onset cirrhosis caused by fatty liver disease

Researchers at University of California San Diego School of Medicine have published the first study to define early-onset cirrhosis caused by metabolic dysfunction-associated steatotic liver disease (MASLD), a condition known as fatty liver disease.

16 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

More data, more answers? A 1.9 million-person health study shows why scale has limits

Researchers analyzed phenotypic and linked health-record data from more than 1.9 million adults in Our Future Health, comparing demographic characteristics, disease patterns, clinical associations, and rare-condition case counts with national data and other major cohorts. The cohort's size provides unusually large samples for many common and less common conditions, although its demographic composition and current data sources require careful consideration when interpreting population-level estimates.

14 Sep 2026

Symptomless liver condition linked to heart and kidney disease

A common liver condition thought to be harmless could be dramatically increasing the risk of heart disease, kidney failure and premature death, according to a new review led by University of Manchester and Northern Care Alliance NHS Foundation Trust researchers.

10 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen. Additional proteomic analyses linked treatment to changes in senescence, metabolism, growth-factor signaling, and fibrosis-related pathways, although the study could not determine whether these effects reflected genuine geroprotection rather than disease modification.

10 Sep 2026

Researchers use an experimental drug to reverse the effects of systemic sclerosis

Investigators at Cedars-Sinai Health Sciences University used an experimental drug to reverse the effects of systemic sclerosis, a serious autoimmune disease. The study, conducted in a laboratory, was published in JCI Insight.

8 Sep 2026

New approach repairs airway barrier defects in cystic fibrosis

A UNIGE team has succeeded in restoring the defective respiratory protective barrier in people with this rare genetic disease.

8 Sep 2026

High-dose flu vaccine protects older adults with lung disease

The risk of being hospitalized for flu or pneumonia can be reduced with a high-dose flu vaccine for older people with chronic lung disease, according to the combined results of two large clinical trials presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain.

8 Sep 2026

Fibrosis News and Research

Further Reading

New artificial intelligence model detects tissue damage in the heart

New framework maps the complex link between psychological status and cardiovascular health

In vivo CAR-T therapy transforms customized treatments into universal medicines

Study identifies shared pathway driving cardiac fibrosis

Mount Sinai researchers discover how Alzheimer's gene damages blood vessels

As GLP-1 drugs become more complex, their effects on the heart are getting harder to predict

Baseline liver fibrosis severity predicts treatment response in patients with HBeAg-positive CHB

Marine carbohydrates offer valuable new resources for drug development

Siemens Healthineers and Novo join forces to advance care for people living with MASLD and MASH

Celastrol reduces cholestatic liver injury by inhibiting specific protein

Study identifies bile acid that helps reduce excess fat accumulation in the liver

Study defines early-onset cirrhosis caused by fatty liver disease

Insilico Medicine launches AI initiative to develop longevity vaccines

More data, more answers? A 1.9 million-person health study shows why scale has limits

Symptomless liver condition linked to heart and kidney disease

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers use an experimental drug to reverse the effects of systemic sclerosis

New approach repairs airway barrier defects in cystic fibrosis

High-dose flu vaccine protects older adults with lung disease

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News